Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.67 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522319 | 0.88 | MAPT (0.57) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL18459774 | 0.86 | MAPT (0.76) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL16061454 | 0.85 | MAPT (0.74) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL18426060 | 0.85 | MAPT (0.74) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL521103 | 0.85 | PKM (0.75) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL6753969 | 0.85 | KDM4E (0.79) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL9642133 | 0.85 | MAPT (1.00) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL7033535 | 0.84 | MAPT (0.91) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL29620259 | 0.84 | KCNJ1 (1.00) | ALDH1A1MAPTLMNAKCNJ1KDM4E | |
| SCHEMBL8601357 | 0.82 | KDM4E (1.00) | ALDH1A1MAPTLMNAKCNJ1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235437-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) MOLECULE FOR DEGRADATION OF ENL AND CANCER THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4496590-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) MOLECULE FOR DEGRADATION OF ENL AND CANCER THERAPY | Baylor College of Medicine (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023183412-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) MOLECULE FOR DEGRADATION OF ENL AND CANCER THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-15 | — | — | US | disclosed |
| US-9382219-B2 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150158830-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-11 | — | — | US | disclosed |
| US-8993567-B2 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| EP-1169038-A4 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004085388-A2 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | DAS JAGABANDHU (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | DAS JAGABANDHU (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | DAS JAGABANDHU (US) | 2004-02-05 | — | — | US | disclosed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| CN-1348370-A | Cyclic protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2002-05-08 | — | — | CN | disclosed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158830-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | ALDH1A1 4758/4885MAPT 3114/4885LMNA 4599/4885 |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | LCK, SSB, JAK1 | ALDH1A1 4643/4885MAPT 3166/4885LMNA 4656/4885 |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | ALDH1A1 4758/4885MAPT 3114/4885LMNA 4599/4885 |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | JAK1, LCK, MERTK | ALDH1A1 3806/4885MAPT 1716/4885LMNA 4799/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | ALDH1A1 4758/4885MAPT 3114/4885LMNA 4599/4885 |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | TPMT, JAK1, CHUK | ALDH1A1 2961/4885MAPT 1908/4885LMNA 4080/4885 |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | ALDH1A1 4758/4885MAPT 3114/4885LMNA 4599/4885 |
| US-20250235437-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) MOLECULE FOR DEGRADATION OF ENL AND CANCER THERAPY | MLLT1, MDM2, PSMA6 | ALDH1A1 3583/4885MAPT 3317/4885LMNA 823/4885 |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | LCK, ABL1, BTK | ALDH1A1 4758/4885MAPT 3114/4885LMNA 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.